Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study describes outcomes of patients with moderate-to-severe plaque psoriasis who switch from ustekinumab to guselkumab in routine clinical care. It includes adults meeting systemic-treatment criteria and who have a medical indication to switch per national psoriasis guidelines. Data collected will reflect real-world use, safety, and effectiveness of guselkumab following prior ustekinumab therapy. No interventional procedures are mandated; results come from standard clinical practice and patient records. Additional details on interventions and endpoints are not specified in the provided materials.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment
* Participants who are currently being treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab, or for whom this switch is medically indicated, based on the current and valid national psoriasis (PsO) therapeutic protocol
* Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab
* Participants must sign an informed consent form (ICF) allowing for data collection and source data verification in accordance with local requirements

Exclusion criteria:

* Contraindication or hypersensitivity to Guselkumab or any other ingredient in the injection solution
* Pregnancy or breastfeeding
* Currently enrolled in an interventional study
* Currently enrolled in an observational study sponsored or managed by a Janssen company
* Previous use of guselkumab in any indication in participant history

Where it's running

• Semmelweis University
  Budapest, Hungary Recruiting

Study contacts

• Study coordinator: Study Contact
• Email: Participate-In-This-Study1@its.jnj.com
• Phone: 844-434-4210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Persistence on Guselkumab in Romanian adults with moderate-to-severe plaque psoriasis

  This study looks at how many adults with moderate-to-severe plaque psoriasis continue guselkumab treatment over two years in Romania.

  Recruiting at 20 sites Janssen Research & Development, LLC · Bârlad and 19 other locations · NCT07582783

• Higher-dose, less-frequent guselkumab versus the usual dose for moderate-to-severe plaque psoriasis in Chinese adults

  This will test whether a higher dose given less often of guselkumab works as well and is as safe as the usual dosing for Chinese adults with moderate-to-severe plaque psoriasis.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07532486

• Guselkumab for adults with Crohn's disease after ustekinumab failure

  This study will try guselkumab for adults with moderate to severe Crohn's disease who did not respond to or could not tolerate ustekinumab to see if they reach remission after 52 weeks.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07487480

• Guselkumab vs Ustekinumab for stricturing Crohn's disease

  This study will follow adults with moderate-to-severe Crohn's disease and confirmed intestinal strictures to see if treatment with guselkumab or ustekinumab better controls obstructive symptoms and disease activity.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07444060

• Adjusting guselkumab dosing schedules for adults with plaque psoriasis

  This project will see if adults with plaque psoriasis who are doing well on guselkumab can safely have their injections spaced farther apart than nine weeks.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice, Alpes Maritimes · NCT07430319

• Guselkumab for Chinese patients with Crohn's disease who stopped responding to ustekinumab

  This study tests whether guselkumab can help Chinese patients with active Crohn's disease who initially responded to ustekinumab but later lost response.

  Recruiting at 5 sites Phase 4 Xian-Janssen Pharmaceutical Ltd. · Guangzhou and 4 other locations · NCT07310095

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.